Exelixis is making solid progress toward that goal. Late last year, it submitted an application to the U.S. Food and Drug ...
To address the dual bottlenecks of immunosuppressive cell infiltration and impaired T-cell function in the tumor microenvironment (TME), researchers from the School of Pharmaceutical Sciences of Sun ...